Sun And Hikma Strike Ilumya Deal
Companies Firm Up Licensing Deal For Tildrakizumab In MENA Region
Executive Summary
Sun has inked another commercial partnership to bring psoriasis drug Ilumya to countries outside India, this time teaming with Hikma in the MENA region.
You may also be interested in...
Hikma Opens Discussions To Acquire GSK OTC, Rx Businesses In Egypt, Tunisia
With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.
Hikma Opens Discussions To Acquire GSK Businesses In Egypt And Tunisia
With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.
Sun Flags Up New Prescriptions Drought Amid COVID-19
Sun Pharma says that the first quarter of 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.